BriaCell Therapeutics Corp.’s (OTCQB: BCTXF) (TSX.V: BCT) Immunotherapy for Advanced Breast Cancer Patients Showing Promising Results

December 21, 2018 09:45:24
  • Confirmation of positive proof-of-concept with lead cancer drug candidate Bria-IMT as monotherapy demonstrates promising anti-tumor activity
  • Off-the-shelf immunotherapies provide customized, cost effective treatment options
  • Positive efficacy data with Bria-IMT was presented at a major breast cancer conference, the 2018 San Antonio Breast Cancer Symposium
  • BriaCell Therapeutics Corp.’s poster presentation at 2018 San Antonio Breast Cancer Symposium now available for public review
  • Global cancer immunotherapy market projected to be worth over $119 billion by 2021

Cancer patients facing limited therapeutic options are the focus for a team of scientists and clinicians at BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), a clinical-stage biotechnology company developing safe and effective immunotherapy treatments for advanced breast cancer patients. BriaCell’s immunotherapy, Bria-IMT, is the company’s lead product candidate. The company recently presented promising results for two of its clinical studies (monotherapy and combination study of Bria-IMT with pembrolizumab [KEYTRUDA®; manufactured by Merck & Co., Inc.]) for patients with advanced breast cancer during the 2018 San Antonio Breast Cancer Symposium in Texas (http://nnw.fm/5YriX).

“I am very excited about our data continuing to show robust biological activity of Bria-IMT™ in advanced breast cancer,” Dr. Bill Williams, BriaCell’s president & CEO, said of the company’s presentation at the international symposium that attracted over 7,000 academic and private physicians and researchers (http://nnw.fm/Po3A0). “These findings also reinforce our product development strategy for Bria-OTS™, BriaCell’s novel off-the-shelf personalized immunotherapy, by showing…

Read More >>

More from NetworkNewsWire

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive instant SMS alerts, text STOCKS to 77948

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com